byiShook Opinion
Apr 2, 2025 - 16:45
TG Therapeutics rallied Wednesday after Roche's rival multiple sclerosis treatment, Ocrevus, missed its mark in a study. The post IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche appeared first on Investor's Business Daily.
TG Therapeutics rallied Wednesday after Roche's rival multiple sclerosis treatment, Ocrevus, missed its mark in a study.
The post IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche appeared first on Investor's Business Daily.